News | May 29, 2023
Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Subscribe To Our Newsletter & Stay Updated
